Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, allowing for unbiased interpretation of compound-specific pathway activity levels, generating terabytes of data for actionable insights [2] - The AP3 platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, which enhance drug discovery beyond traditional methods [2] Clinical Programs - Acrivon's lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-368 has also received Breakthrough Device designation for its OncoSignature assay to identify suitable patients for treatment [3] - The second clinical asset, ACR-2316, is a WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data through a conference call and webcast in January 2026, including interim data from the Phase 2b study and the Phase 1 study of ACR-2316 [1][6]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, providing rapid and actionable insights from terabytes of proprietary data [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, allowing for advanced drug discovery beyond traditional methods [2] Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a potent WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data via a conference call and webcast in January 2026, including interim data from ongoing trials and new preclinical candidates [1][6]

The Dow Jones Industrial Average rose 116 points, or 0.2%. The S&P 500 was up 0.1%. The Nasdaq Composite was up 0.1%. "After a busy day for data yesterday, the calendar goes dark again this morning, but there is some Fedspeak to fill the void,†writes Bespoke Investment Group co-founder Paul Hickey. Stocks opened modestly higher on Wednesday, as the S&P 500 moved to shake off its latest losing streak. ...

We recently published 10 Best SaaS Stocks Trading at a Discount.  Cemtrex, Inc. (NASDAQ:CETX) is one of the best Saas stocks trading at a discount. Cemtrex, Inc. (NASDAQ:CETX) is a technology company that operates in the SaaS industry through its security business, Vicon, which provides video management software. The firm made a key set of announcements on December 11th when it revealed that it was nearing the close of an acquisition of a Texas aerospace and defense engineering company. Cemtrex, Inc. (NAS ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Morgan Stanley upgraded Rollins (ROL) to Overweight from Equal Weight with a price target of $72, up from $58. The firm says the company is a "best-in-class" operator with durable demand drivers, a resilient end market, and structural tailwinds.DA Davidson upgraded Guidewire (GWRE) to Buy from Neutral with an unch ...

Core Insights - RLWRLD, a Physical AI startup, won first place in the Foundation Models, Robot Brains and Runtime category at the 2025 Nebius Robotics & Physical AI Awards, highlighting its advancements in next-generation robotics and Physical AI [2][3][5] Group 1: Awards and Recognition - The Nebius Robotics & Physical AI Awards, hosted by Nebius and supported by NVIDIA, awarded $1.5 million in AI cloud compute and inference credits to startups from over 250 applicants across 60+ countries [3][5] - RLWRLD received $150,000 in Nebius AI Cloud compute and inference credits as the first-place winner, emphasizing its innovative contributions to the field [5] Group 2: Company Focus and Technology - RLWRLD specializes in developing robot foundation models for high-difficulty manipulation and reliable industrial deployment, focusing on practical applications rather than general-purpose robotics [6][8] - The company's core platform, RLDX, is a proprietary robotics foundation model that controls a 15-degree-of-freedom robotic hand, enabling tasks that require human-level dexterity [6] Group 3: Commercial Readiness and Partnerships - Judges recognized RLWRLD's use of high-fidelity, multimodal industrial data and its collaboration with industry partners as indicators of commercial readiness, particularly in manufacturing and logistics [7] - Following the award, RLWRLD plans to expand global partnerships and accelerate the commercial deployment of its foundation models, focusing on manufacturing and logistics environments in the U.S. and Asia [8] Group 4: Company Background - Founded in 2024, RLWRLD develops robot foundation models that enable machines to operate with human-like dexterity and cognition, utilizing high-precision 4D+ multimodal industrial data [9] - The company operates in the United States, South Korea, and Japan, and is working with major manufacturing partners to establish itself as a global leader in industrial robotics AI [9]

Core Insights - Acentra Health has appointed Meghan Harris as a member of its board of directors, reflecting her significant impact on the company's strategic direction and operational leadership [1][3] Company Overview - Acentra Health is a technology and health solutions company focused on improving health outcomes for government and commercial clients [1][6] - The company combines public sector knowledge, clinical expertise, and technological innovation to modernize healthcare experiences [6] Leadership and Experience - Meghan Harris brings over 20 years of experience in healthcare quality improvement, strategic operations, and client-focused innovation to the board [2] - As President and COO, Harris oversees all public and commercial operations, solution development, quality, and contract implementations [2] Strategic Impact - Under Harris' leadership, Acentra Health has retained contracts and experienced year-over-year contract growth, indicating strong operational performance [4] - Harris has been instrumental in developing integrated solutions that address emerging healthcare delivery needs and policy priorities [4] Educational Background - Meghan Harris holds a Bachelor of Science degree in mathematics from Malone College and a Master of Science degree in statistics from the University of Akron [5]

Paramount Skydance's hostile bid for Warner Bros. Discovery appeared to be on shakier ground Wednesday, after the Warner Bros. ...

Core Insights - Hologic's AI-powered mammography solutions are gaining traction in clinical settings, particularly with the 3DQuorum technology, which enhances radiologists' workflows and maintains high cancer detection effectiveness [1] - The Genius AI Detection solution has demonstrated comparable performance to radiologists in identifying challenging breast cancer cases, with new data indicating its potential to increase cancer detection rates [1][9] Technology Performance - A study involving 7,500 digital breast tomosynthesis exams revealed that the Genius AI Detection solution flagged approximately 32% of false-negative mammograms, accurately identifying the location of breast cancer in one-third of these cases [2][3][9] - The AI technology successfully flagged nearly 90% of previously identified breast cancer cases by radiologists, showing a higher likelihood of detecting invasive ductal carcinomas and lymph node-positive cancers [4] Study Limitations - The study's findings may not be generalizable due to its single-center design, predominantly Caucasian patient population, and the use of a specific version of the AI software, which limits the applicability of results to other settings or algorithms [5] Industry Updates - GE Healthcare announced a contract to supply over 300 CT scanners to Indonesia, aiming to improve healthcare access for over 280 million people [6] - Becton, Dickinson and Company is expanding its diagnostic offerings in Europe, focusing on respiratory and STI diagnostics with new assays developed in partnership with Certest Biotec [7] Stock Performance and Valuation - Hologic's stock has increased by 10% over the past three months, outperforming the industry growth of 8.6% [8] - The company is currently trading at a forward five-year price-to-sales ratio of 3.86X, which is lower than the industry average of 4.36X [10]

Key Takeaways XOM targets $25B earnings growth by 2030 without raising capex, led by Guyana, Permian and LNG assets.CVX plans 2026 capex of $18-$19B, favoring capital discipline and sustaining returns in weak price cycles.XOM trades at 16X forward earnings vs. CVX at 20X, reflecting differences in growth outlook.ExxonMobil (XOM) and Chevron (CVX) remain two of the most influential integrated oil majors, but 2025 has been a mixed year for both stocks. Year to date, ExxonMobil shares are up about 6.6% while C ...